参考文献/References:
[1] Whaley-Connell A,Sowers JR. Basic science:pathophysiology:the cardiorenal metabolic syndrome[J]. J Am Soc Hypertens,2014,8(8):604-606.
[2] Ndumele CE,Rangaswami J,Chow SL,et al. Cardiovascular-kidney-metabolic health:a presidential advisory from the American Heart Association[J]. Circulation,2023,148(20):1606-1635.
[3] Ndumele CE,Neeland IJ,Tuttle KR,et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome:a scientific statement from the American Heart Association[J]. Circulation,2023,148(20):1636-1664.
[4] Arnold SV,Kosiborod M,Wang J,et al. Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the diabetes collaborative registry[J]. Diabetes Obes Metab,2018,20(8):2000-2003.
[5] Ostrominski JW,Thierer J,Claggett BL,et al. Cardio-renal-metabolic overlap,outcomes,and dapagliflozin in heart failure with mildly reduced or preserved ejection fraction[J]. JACC Heart Fail,2023,11(11):1491-1503.
[6] Jin Q,Luk AO,Lau ESH,et al. Nonalbuminuric diabetic kidney disease and risk of all-cause mortality and cardiovascular and kidney outcomes in type 2 diabetes:findings from the Hong Kong diabetes biobank[J]. Am J Kidney Dis,2022,80(2):196-206 e1.
[7] Fernandez-Friera L,Fuster V,Lopez-Melgar B,et al. Normal LDL-cholesterol levels are associated with subclinical atherosclerosis in the absence of risk factors[J]. J Am Coll Cardiol,2017,70(24):2979-2991.
[8] Palanca A,Castelblanco E,Perpinan H,et al. Prevalence and progression of subclinical atherosclerosis in patients with chronic kidney disease and diabetes[J]. Atherosclerosis,2018,276:50-57.
[9] Palanca A,Castelblanco E,Betriu A,et al. Subclinical atherosclerosis burden predicts cardiovascular events in individuals with diabetes and chronic kidney disease[J]. Cardiovasc Diabetol,2019,18(1):93.
[10] Zhou Z,Macpherson J,Gray SR,et al. Are people with metabolically healthy obesity really healthy? A prospective cohort study of 381,363 UK biobank participants[J]. Diabetologia,2021,64(9):1963-1972.
[11] Zuo Y,Han X,Tian X,et al. Association of impaired fasting glucose with cardiovascular disease in the absence of risk factor[J]. J Clin Endocrinol Metab,2022,107(4):e1710-e1718.
[12] Jee Y,Ryu M,Ryou IS,et al. Mediators of the effect of obesity on stroke and heart disease risk:decomposing direct and indirect effects[J]. J Epidemiol,2023,33(10):514-520.
[13] Wu H,Ballantyne CM. Metabolic inflammation and insulin resistance in obesity[J]. Circ Res,2020,126(11):1549-1564.
[14] Huang WH,Xue YJ,Zhou YJ,et al. KLF7 promotes macrophage activation by activating the NF-kappaB signaling pathway in epicardial adipose tissue in patients with coronary artery disease[J]. Eur Rev Med Pharmacol Sci,2020,24(12):7002-7014.
[15] Ma ZP,Wang SW,Xue LY,et al. A study on the application of radiomics based on cardiac MR non-enhanced cine sequence in the early diagnosis of hypertensive heart disease[J]. BMC Med Imaging,2024,24(1):124.
[16] Yan SF,Ramasamy R,Schmidt AM. The RAGE axis:a fundamental mechanism signaling danger to the vulnerable vasculature[J]. Circ Res,2010,106(5):842-853.
[17] Tajbakhsh A,Kovanen PT,Rezaee M,et al. Regulation of efferocytosis by caspase-dependent apoptotic cell death in atherosclerosis[J]. Int J Biochem Cell Biol,2020,120:105684.
[18] Peng X,Zhang HP. Acute cardiorenal syndrome:epidemiology,pathophysiology,assessment,and treatment[J]. Rev Cardiovasc Med,2023,24(2):40.
[19] Dusing P,Zietzer A,Goody PR,et al. Vascular pathologies in chronic kidney disease:pathophysiological mechanisms and novel therapeutic approaches[J]. J Mol Med (Berl),2021,99(3):335-348.
[20] Zinman B,Wanner C,Lachin JM,et al. Empagliflozin,cardiovascular outcomes,and mortality in type 2 diabetes[J]. N Engl J Med,2015,373(22):2117-2128.
[21] Neal B,Perkovic V,Mahaffey KW,et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. N Engl J Med,2017,377(7):644-657.
[22] Wiviott SD,Raz I,Bonaca MP,et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med,2019,380(4):347-357.
[23] Seo B,Su J,Song Y. Exploring heterogeneities of cardiovascular efficacy and effectiveness of SGLT2 inhibitors in patients with type 2 diabetes:an umbrella review of evidence from randomized clinical trials versus real-world observational studies[J]. Eur J Clin Pharmacol,2022,78(8):1205-1216.
[24] Georgianos PI,Agarwal R. Ambulatory blood pressure reduction with SGLT-2 inhibitors:dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide[J]. Diabetes Care,2019,42(4):693-700.
[25] Frias J P,Guja C,Hardy E,et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8):a 28 week,multicentre,double-blind,phase 3,randomised controlled trial[J]. Lancet Diabetes Endocrinol,2016,4(12):1004-1016.
[26] Wang X,Wu N,Sun C,et al. Effects of SGLT-2 inhibitors on adipose tissue distribution in patients with type 2 diabetes mellitus:a systematic review and meta-analysis of randomized controlled trials[J]. Diabetol Metab Syndr,2023,15(1):113.
[27] Zelniker TA,Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors:JACC state-of-the-art review[J]. J Am Coll Cardiol,2020,75(4):422-434.
[28] Marso SP,Daniels GH,Brown-Frandsen K,et al. Liraglutide and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med,2016,375(4):311-322.
[29] Marso SP,Bain SC,Consoli A,et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med,2016,375(19):1834-1844.
[30] Gerstein HC,Colhoun HM,Dagenais GR,et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND):a double-blind,randomised placebo-controlled trial[J]. Lancet,2019,394(10193):121-130.
[31] Sattar N,Lee MMY,Kristensen SL,et al. Cardiovascular,mortality,and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes:a systematic review and meta-analysis of randomised trials[J]. Lancet Diabetes Endocrinol,2021,9(10):653-662.
[32] Marx N,Federici M,Schutt K,et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes[J]. Eur Heart J,2023,44(39):4043-4140.
[33] Rizzo M,Rizvi AA,Patti AM,et al. Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome:an 18-month prospective study[J]. Cardiovasc Diabetol,2016,15(1):162.
[34] Sorli C,Harashima SI,Tsoukas GM,et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1):a double-blind,randomised,placebo-controlled,parallel-group,multinational,multicentre phase 3a trial[J]. Lancet Diabetes Endocrinol,2017,5(4):251-260.
[35] Weinstock RS,Guerci B,Umpierrez G,et al. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5):a randomized,phase Ⅲ study[J]. Diabetes Obes Metab,2015,17(9):849-958.
[36] Sun F,Wu S,Wang J,et al. Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes:a systematic review and network meta-analysis[J]. Clin Ther,2015,37(1):225-241.e8.
[37] Agarwal R,Filippatos G,Pitt B,et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease:the FIDELITY pooled analysis[J]. Eur Heart J,2022,43(6):474-484.
[38] Pitt B,Filippatos G,Agarwal R,et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes[J]. N Engl J Med,2021,385(24):2252-2263.
[39] Filippatos G,Anker SD,Pitt B,et al. Finerenone efficacy in patients with chronic kidney disease,type 2 diabetes and atherosclerotic cardiovascular disease[J]. Eur Heart J Cardiovasc Pharmacother,2022,9(1):85-93.
[40] Jiang X,Mahfoud F,Li W,et al. Efficacy and safety of catheter-based radiofrequency renal denervation in chinese patients with uncontrolled hypertension:the randomized,sham-controlled,multi-center iberis-HTN trial[J]. Circulation,2024,150(20):1588-1598.
[41] Reyes KRL,Rader F. Long-term safety and antihypertensive effects of renal denervation:current insights[J]. Integr Blood Press Control,2023,16:59-70.
[42] Mahfoud F,Mancia G,Schmieder R,et al. Renal denervation in high-risk patients with hypertension[J]. J Am Coll Cardiol,2020,75(23):2879-2888.
[43] Chen H,Wang R,Xu F,et al. Renal denervation mitigates atherosclerosis in ApoE-/- mice via the suppression of inflammation [J]. Am J Transl Res,2020,12(9):5362-5380.
[44] Mahfoud F,Schlaich M,Kindermann I,et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension:a pilot study[J]. Circulation,2011,123(18):1940-1946.
[45] Kiuchi MG,Carnagarin R,Matthews VB,et al. Multi-organ denervation:a novel approach to combat cardiometabolic disease[J]. Hypertens Res,2023,46(7):1747-1758.
相似文献/References:
[1]史云聪 郭艺芳.2型糖尿病和动脉粥样硬化性心血管疾病的关系[J].心血管病学进展,2020,(5):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
SHI Yuncong,GUO Yifang.Relationship Between Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(4):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
[2]李艳茹,白世茹,李如意,等.PCSK9抑制剂在血脂代谢中的研究进展[J].心血管病学进展,2020,(7):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
LI Yanru,BAI Shiru,LI Ruyi,et al.PCSK9 Inhibitors in Lipid Metabolism[J].Advances in Cardiovascular Diseases,2020,(4):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
[3]马晓磊 朱国斌.Wnt信号与动脉粥样硬化性心血管疾病研究进展[J].心血管病学进展,2020,(8):855.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.018]
MA Xiaolei,ZHU Guobin.Wnt Signaling and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(4):855.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.018]
[4]黄毕.慢性肾脏病合并动脉粥样硬化性心血管疾病的调脂治疗进展[J].心血管病学进展,2020,(10):1065.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.016]
HUANG Bi.Lipid Management in Patients with Chronic Kidney Disease and Arteriosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(4):1065.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.016]
[5]姚雅洁 蔡恒.PCSK9抑制剂Evolocumab动脉粥样硬化性心血管疾病的研究进展[J].心血管病学进展,2020,(12):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
YAO Yajie,CAI Heng.PCSK9 Inhibitor Evolocumab and ASCVD[J].Advances in Cardiovascular Diseases,2020,(4):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
[6]曹岩 颜培实.残余胆固醇与动脉粥样硬化性心血管疾病[J].心血管病学进展,2021,(10):920.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.014]
CAO Yan,YAN Peishi.Remnant Cholesterol And Atherosclerotic?ardiovascular Disease[J].Advances in Cardiovascular Diseases,2021,(4):920.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.014]
[7]蔡薇 杨堰焯 刘昊凌.甘油三酯葡萄糖乘积指数与糖尿病血管病变的研究进展[J].心血管病学进展,2022,(3):245.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
CAI Wei,YANG Yanzhuo,LIU Haoling.Triglyceride-Glucose Index and Diabetic Vascular Disease[J].Advances in Cardiovascular Diseases,2022,(4):245.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[8]陈林滔 田清平 刘梅林.残余胆固醇预测动脉粥样硬化性心血管疾病的研究进展[J].心血管病学进展,2022,(6):492.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.004]
CHEN Lintao,TIAN Qingping,LIU Meilin.Remnant Cholesterol in Predicting Atherosclerotic Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2022,(4):492.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.004]
[9].胆固醇酯转移蛋白抑制剂在动脉粥样硬化性心血管疾病治疗中的研究进展[J].心血管病学进展,2022,(7):600.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
ZHU Jie,GAO Fen,XUE Shuanqin,et al.Treatment of Atherosclerotic Cardiovascular Diseases with Cholesteryl Ester Transfer Protein Inhibitor[J].Advances in Cardiovascular Diseases,2022,(4):600.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[10]欧阳运峰 李皇庆 李璐 阳军.脂蛋白a：动脉粥样硬化性心血管疾病防治新靶点[J].心血管病学进展,2022,(8):731.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.016]
OUYANG Yunfeng,LI Huangqing,LI Lu,et al.Lipoprotein A:a New Target for Prevention and Treatment of Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2022,(4):731.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.016]